Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment

American Journal of Therapeutics

Volumn 14, Issue 4, 2007, Pages 414-416

  Razaq, Mohammad ^a   Balicas, Madelyn ^a   Mankan, Nagender ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Hepatic impairment; Hydromorphone; Morphine; Opioids; Renal insufficiency

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROMORPHONE; MORPHINE;

AGED; ANTINOCICEPTION; ARTICLE; BACKACHE; CASE REPORT; CLINICAL FEATURE; DROWSINESS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER FAILURE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANALGESICS, OPIOID; BACK PAIN; HEPATIC INSUFFICIENCY; HUMANS; HYDROMORPHONE; MALE; MORPHINE; MULTIPLE MYELOMA; RENAL INSUFFICIENCY;

EID: 34547670252     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pap.0000249926.89087.d8     Document Type: Article

References (19)

1. Rifkin BS, Prazella MA. Analgesic therapy in patients with chronic kidney disease. Clinical review article. Hosp Phys. 2005;41:13-21.
2. Durnin C, Hind ID, Wickens MM, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc. 2001;44:81-2.
3. Drug Information Service. Drug use in liver impairment, no. 67. Canterbury, NZ: Canterbury DHB District Health Board, 2003.
4. Kuczynska J. Drugs in renal failure. Opioid Analgesics Version I. Bristol: South West Medicines Information and Training, 2004.
5. Warfield C, Bajwa ZH. Principles and practice of pain medicine. In: Lipman AG, Kenneth CJII (eds). Opioid Pharmacotherapy, 2nd ed. New York: McGraw Hill; 2004: 590-591.
6. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24:344-354.
7. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain, and side effects during longterm treatment: an update. J Pain Symptom Manage. 2003;25:74-91.
8. Patwardhan RV, Johnson RF, Hoyumpa A Jr, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981;81:1006-1011.
9. Pereira J, Bruera E. Emerging neuropsychiatric toxicities of opioids. J Pharm Care Pain Sympt Control. 1997;5:3.
10. Forman W. Opioid analgesic drugs in the elderly. Clin Geriatr Med. 1996:12:489.
11. Sjogren P, Dragsted L, Christensen CB. Myoclonus spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiology Scand. 1993:37:780-782.
12. Shelly MP, Sneyd, R. Intensive care sedation. Br J Intensive Care. 1992:323.
13. Levy J. Oxford Handbook of Dialysis. Oxford: Oxford University Press; 2001:561
14. D'Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentration morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology. 1994;81:87-93.
15. Bunn R, Ashley C. The Renal Drug Handbook. Oxford: Radcliffe Medical Press, 1999.
16. Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc. 2001;44:83-84.
17. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42:217-228.
18. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15:26-4.
19. Rich A. The role of palliative care in patients with renal failure. Brit J Renal Med. 2000;5:6-8.